[Form 4] Immunome, Inc. Insider Trading Activity
Immunome Inc. (IMNM) filed a Form 4 for Chief Medical Officer Dr. Robert Lechleider, reporting the grant of 242,000 employee stock options on 07/29/2025. The options carry a $10.60 exercise price and expire on 07/28/2035. Vesting terms: 25 % on 07/29/2026, then monthly vesting of the remaining 75 % over 36 months, leading to full vesting by 07/29/2029. After the award, the CMO beneficially owns 242,000 derivative securities; no common-stock holdings or open-market trades were disclosed. The transaction is coded 鈥淎鈥� (grant) and is held directly; no 10b5-1 plan was indicated. The filing represents standard incentive compensation with no immediate share dilution or cash impact for investors.
Immunome Inc. (IMNM) ha presentato un Modulo 4 per il Chief Medical Officer Dr. Robert Lechleider, comunicando la concessione di 242.000 opzioni azionarie per dipendenti il 29/07/2025. Le opzioni hanno un prezzo di esercizio di 10,60 $ e scadono il 28/07/2035. Condizioni di maturazione: 25% il 29/07/2026, poi maturazione mensile del restante 75% in 36 mesi, con piena maturazione entro il 29/07/2029. Dopo l鈥檃ssegnazione, il CMO possiede beneficiariamente 242.000 strumenti derivati; non sono state dichiarate partecipazioni in azioni ordinarie n茅 operazioni sul mercato aperto. La transazione 猫 classificata come 鈥淎鈥� (concessione) ed 猫 detenuta direttamente; non 猫 stato indicato alcun piano 10b5-1. La comunicazione rappresenta una normale forma di compenso incentivante senza immediata diluizione delle azioni o impatto in contanti per gli investitori.
Immunome Inc. (IMNM) present贸 un Formulario 4 para el Director M茅dico Dr. Robert Lechleider, reportando la concesi贸n de 242,000 opciones sobre acciones para empleados el 29/07/2025. Las opciones tienen un precio de ejercicio de $10.60 y vencen el 28/07/2035. Condiciones de adquisici贸n: 25 % el 29/07/2026, luego adquisici贸n mensual del 75 % restante durante 36 meses, alcanzando la adquisici贸n total para el 29/07/2029. Tras la adjudicaci贸n, el CMO posee beneficiosamente 242,000 valores derivados; no se revelaron participaciones en acciones comunes ni operaciones en el mercado abierto. La transacci贸n est谩 codificada como 鈥淎鈥� (concesi贸n) y se mantiene directamente; no se indic贸 ning煤n plan 10b5-1. La presentaci贸n representa una compensaci贸n por incentivos est谩ndar sin diluci贸n inmediata de acciones ni impacto en efectivo para los inversores.
Immunome Inc. (IMNM)電� 斓滉碃 鞚橂 毂呾瀯鞛� Dr. Robert Lechleider鞐� 雽�頃� 2025雲� 7鞗� 29鞚检棎 242,000臧滌潣 歆侅洂 鞀ろ啞 鞓奠厴 攵�鞐ゼ 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞓奠厴 頄夓偓臧�瓴╈潃 $10.60鞚措┌ 毵岆鞚检潃 2035雲� 7鞗� 28鞚检瀰雼堧嫟. 甓岆Μ 旆摑 臁瓣贝鞚� 2026雲� 7鞗� 29鞚检棎 25% 攵�鞐� 頉�, 雮橂ǜ歆� 75%電� 36臧滌洈 霃欖晥 鞗旊硠搿� 甓岆Μ 旆摑霅橃柎 2029雲� 7鞗� 29鞚缄箤歆� 鞕勳爠 甓岆Μ 旆摑霅╇媹雼�. 靾橃棳 頉� CMO電� 242,000臧滌潣 韺岇儩 歃濌秾鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橂┌, 氤错喌欤� 氤挫湢雮� 瓿店皽 鞁滌灔 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 瓯半灅電� 鈥淎鈥�(攵�鞐�)搿� 攵勲霅橂┌ 歆侅爲 氤挫湢霅橁碃, 10b5-1 瓿勴殟鞚� 氇呾嫓霅橃 鞎婌晿鞀惦媹雼�. 鞚措矆 氤搓碃電� 韴瀽鞛愳棎瓴� 歃夑皝鞝侅澑 欤检嫕 頋劃鞚措倶 順勱笀 鞓來枼 鞐嗢澊 響滌 鞚胳劶韹半笇 氤挫儊鞚� 雮橅儉雰呺媹雼�.
Immunome Inc. (IMNM) a d茅pos茅 un formulaire 4 pour le directeur m茅dical Dr. Robert Lechleider, signalant l鈥檕ctroi de 242 000 options d鈥檃chat d鈥檃ctions pour employ茅s le 29/07/2025. Les options ont un prix d鈥檈xercice de 10,60 $ et expirent le 28/07/2035. Modalit茅s d鈥檃cquisition : 25 % le 29/07/2026, puis acquisition mensuelle des 75 % restants sur 36 mois, aboutissant 脿 une acquisition compl猫te au 29/07/2029. Apr猫s l鈥檃ttribution, le CMO d茅tient b茅n茅ficiairement 242 000 titres d茅riv茅s ; aucune d茅tention d鈥檃ctions ordinaires ni transaction sur le march茅 ouvert n鈥檃 茅t茅 divulgu茅e. La transaction est cod茅e 芦 A 禄 (octroi) et d茅tenue directement ; aucun plan 10b5-1 n鈥檃 茅t茅 indiqu茅. Le d茅p么t repr茅sente une r茅mun茅ration incitative standard sans dilution imm茅diate des actions ni impact en tr茅sorerie pour les investisseurs.
Immunome Inc. (IMNM) reichte ein Formular 4 f眉r den Chief Medical Officer Dr. Robert Lechleider ein und meldete die Gew盲hrung von 242.000 Mitarbeiter-Aktienoptionen am 29.07.2025. Die Optionen haben einen Aus眉bungspreis von 10,60 $ und verfallen am 28.07.2035. Vesting-Bedingungen: 25 % am 29.07.2026, danach monatliche Vesting der verbleibenden 75 % 眉ber 36 Monate, mit vollst盲ndigem Vesting bis zum 29.07.2029. Nach der Zuteilung besitzt der CMO wirtschaftlich 242.000 Derivatwerte; keine Stammaktienbest盲nde oder B枚rsentransaktionen wurden offengelegt. Die Transaktion ist als 鈥濧鈥� (Gew盲hrung) codiert und wird direkt gehalten; ein 10b5-1-Plan wurde nicht angegeben. Die Meldung stellt eine 眉bliche Anreizverg眉tung ohne sofortige Aktienverw盲sserung oder Liquidit盲tsauswirkung f眉r Investoren dar.
- 242,000 options granted at market price aligns C-suite incentives with shareholder value appreciation
- None.
Insights
TL;DR: 242k options granted to CMO at $10.60; standard four-year vesting aligns management with shareholders, negligible near-term dilution.
The award size is meaningful for a mid-cap biotech but falls within typical executive compensation ranges. Setting the strike at market price creates performance alignment: value is only realized if shares appreciate beyond $10.60. Four-year vesting helps retain key scientific leadership through pivotal development milestones. Because no shares were issued today, dilution occurs only upon future exercise, and even then represents roughly 0.8-1 % of current shares outstanding鈥攊mmaterial in the near term. Overall impact on valuation or cash flow is neutral.
TL;DR: Routine insider option grant; signals commitment but lacks material effect on fundamentals鈥攎onitor future exercises.
This Form 4 does not indicate insider buying or selling, merely the granting of options. Such grants are common after senior hires or performance reviews. Investors should note the long-dated expiration (2035), which can become dilutive over time, yet the percentage versus float is modest. No red flags emerge, and the absence of a 10b5-1 reference suggests flexibility in future trading windows. I classify the filing as not impactful to the current investment thesis but useful for tracking insider incentive structures.
Immunome Inc. (IMNM) ha presentato un Modulo 4 per il Chief Medical Officer Dr. Robert Lechleider, comunicando la concessione di 242.000 opzioni azionarie per dipendenti il 29/07/2025. Le opzioni hanno un prezzo di esercizio di 10,60 $ e scadono il 28/07/2035. Condizioni di maturazione: 25% il 29/07/2026, poi maturazione mensile del restante 75% in 36 mesi, con piena maturazione entro il 29/07/2029. Dopo l鈥檃ssegnazione, il CMO possiede beneficiariamente 242.000 strumenti derivati; non sono state dichiarate partecipazioni in azioni ordinarie n茅 operazioni sul mercato aperto. La transazione 猫 classificata come 鈥淎鈥� (concessione) ed 猫 detenuta direttamente; non 猫 stato indicato alcun piano 10b5-1. La comunicazione rappresenta una normale forma di compenso incentivante senza immediata diluizione delle azioni o impatto in contanti per gli investitori.
Immunome Inc. (IMNM) present贸 un Formulario 4 para el Director M茅dico Dr. Robert Lechleider, reportando la concesi贸n de 242,000 opciones sobre acciones para empleados el 29/07/2025. Las opciones tienen un precio de ejercicio de $10.60 y vencen el 28/07/2035. Condiciones de adquisici贸n: 25 % el 29/07/2026, luego adquisici贸n mensual del 75 % restante durante 36 meses, alcanzando la adquisici贸n total para el 29/07/2029. Tras la adjudicaci贸n, el CMO posee beneficiosamente 242,000 valores derivados; no se revelaron participaciones en acciones comunes ni operaciones en el mercado abierto. La transacci贸n est谩 codificada como 鈥淎鈥� (concesi贸n) y se mantiene directamente; no se indic贸 ning煤n plan 10b5-1. La presentaci贸n representa una compensaci贸n por incentivos est谩ndar sin diluci贸n inmediata de acciones ni impacto en efectivo para los inversores.
Immunome Inc. (IMNM)電� 斓滉碃 鞚橂 毂呾瀯鞛� Dr. Robert Lechleider鞐� 雽�頃� 2025雲� 7鞗� 29鞚检棎 242,000臧滌潣 歆侅洂 鞀ろ啞 鞓奠厴 攵�鞐ゼ 氤搓碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞓奠厴 頄夓偓臧�瓴╈潃 $10.60鞚措┌ 毵岆鞚检潃 2035雲� 7鞗� 28鞚检瀰雼堧嫟. 甓岆Μ 旆摑 臁瓣贝鞚� 2026雲� 7鞗� 29鞚检棎 25% 攵�鞐� 頉�, 雮橂ǜ歆� 75%電� 36臧滌洈 霃欖晥 鞗旊硠搿� 甓岆Μ 旆摑霅橃柎 2029雲� 7鞗� 29鞚缄箤歆� 鞕勳爠 甓岆Μ 旆摑霅╇媹雼�. 靾橃棳 頉� CMO電� 242,000臧滌潣 韺岇儩 歃濌秾鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橂┌, 氤错喌欤� 氤挫湢雮� 瓿店皽 鞁滌灔 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�. 瓯半灅電� 鈥淎鈥�(攵�鞐�)搿� 攵勲霅橂┌ 歆侅爲 氤挫湢霅橁碃, 10b5-1 瓿勴殟鞚� 氇呾嫓霅橃 鞎婌晿鞀惦媹雼�. 鞚措矆 氤搓碃電� 韴瀽鞛愳棎瓴� 歃夑皝鞝侅澑 欤检嫕 頋劃鞚措倶 順勱笀 鞓來枼 鞐嗢澊 響滌 鞚胳劶韹半笇 氤挫儊鞚� 雮橅儉雰呺媹雼�.
Immunome Inc. (IMNM) a d茅pos茅 un formulaire 4 pour le directeur m茅dical Dr. Robert Lechleider, signalant l鈥檕ctroi de 242 000 options d鈥檃chat d鈥檃ctions pour employ茅s le 29/07/2025. Les options ont un prix d鈥檈xercice de 10,60 $ et expirent le 28/07/2035. Modalit茅s d鈥檃cquisition : 25 % le 29/07/2026, puis acquisition mensuelle des 75 % restants sur 36 mois, aboutissant 脿 une acquisition compl猫te au 29/07/2029. Apr猫s l鈥檃ttribution, le CMO d茅tient b茅n茅ficiairement 242 000 titres d茅riv茅s ; aucune d茅tention d鈥檃ctions ordinaires ni transaction sur le march茅 ouvert n鈥檃 茅t茅 divulgu茅e. La transaction est cod茅e 芦 A 禄 (octroi) et d茅tenue directement ; aucun plan 10b5-1 n鈥檃 茅t茅 indiqu茅. Le d茅p么t repr茅sente une r茅mun茅ration incitative standard sans dilution imm茅diate des actions ni impact en tr茅sorerie pour les investisseurs.
Immunome Inc. (IMNM) reichte ein Formular 4 f眉r den Chief Medical Officer Dr. Robert Lechleider ein und meldete die Gew盲hrung von 242.000 Mitarbeiter-Aktienoptionen am 29.07.2025. Die Optionen haben einen Aus眉bungspreis von 10,60 $ und verfallen am 28.07.2035. Vesting-Bedingungen: 25 % am 29.07.2026, danach monatliche Vesting der verbleibenden 75 % 眉ber 36 Monate, mit vollst盲ndigem Vesting bis zum 29.07.2029. Nach der Zuteilung besitzt der CMO wirtschaftlich 242.000 Derivatwerte; keine Stammaktienbest盲nde oder B枚rsentransaktionen wurden offengelegt. Die Transaktion ist als 鈥濧鈥� (Gew盲hrung) codiert und wird direkt gehalten; ein 10b5-1-Plan wurde nicht angegeben. Die Meldung stellt eine 眉bliche Anreizverg眉tung ohne sofortige Aktienverw盲sserung oder Liquidit盲tsauswirkung f眉r Investoren dar.
FAQ
How many stock options were granted to IMNM's CMO?
What is the exercise price of the Immunome (IMNM) options?
When do the IMNM options vest?
What is the expiration date of the granted options?
Did the CMO buy or sell any Immunome common stock?
